As HUTCHMED’s pipeline of novel cancer drugs gains approval on the international stage, WHAM helped the biopharma consolidate their disparate identities into one; signalling a new chapter for the Hong Kong-headquartered company. The project focused on creating a new name and visual identity that would build on existing brand equity, whilst symbolising their future-focused ambition to improve the lives of patients globally. WHAM also assisted in rolling out the new identity, via the 2020 annual report and website, and with film and social media content to support the 2021 investor briefing, where the new identity was launched.